MA44056A - Anticorps anti-rispéridone et leur utilisation - Google Patents

Anticorps anti-rispéridone et leur utilisation

Info

Publication number
MA44056A
MA44056A MA044056A MA44056A MA44056A MA 44056 A MA44056 A MA 44056A MA 044056 A MA044056 A MA 044056A MA 44056 A MA44056 A MA 44056A MA 44056 A MA44056 A MA 44056A
Authority
MA
Morocco
Prior art keywords
risperidone
antibodies
risperidone antibodies
Prior art date
Application number
MA044056A
Other languages
English (en)
Inventor
Linda Colt
Thomas R Decory
Pieter Rik Haspeslagh
Eric Hryhorenko
Banumathi Sankaran
Theresa Tubbs
Maarten Vliegen
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MA44056A publication Critical patent/MA44056A/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
MA044056A 2015-12-17 2016-12-15 Anticorps anti-rispéridone et leur utilisation MA44056A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562268898P 2015-12-17 2015-12-17

Publications (1)

Publication Number Publication Date
MA44056A true MA44056A (fr) 2018-10-24

Family

ID=57708858

Family Applications (1)

Application Number Title Priority Date Filing Date
MA044056A MA44056A (fr) 2015-12-17 2016-12-15 Anticorps anti-rispéridone et leur utilisation

Country Status (8)

Country Link
US (2) US10444250B2 (fr)
EP (1) EP3390449A1 (fr)
JP (1) JP6949025B2 (fr)
CN (1) CN108431040B (fr)
AU (1) AU2016372069A1 (fr)
CA (1) CA3008809A1 (fr)
MA (1) MA44056A (fr)
WO (1) WO2017106501A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014031645A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
PT3462173T (pt) 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
CA2882489A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de paliperidone et leur utilisation
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
CN112730825B (zh) * 2020-12-17 2022-09-06 北京丹大生物技术有限公司 一种用于检测利培酮和/或9-羟基利培酮的检测试剂和检测试剂盒
CN115927347B (zh) * 2022-10-14 2026-01-16 杭州佰辰医学检验所有限公司 特异性结合利培酮的核酸适配体及衍生物、应用、试剂盒

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5576195A (en) 1985-11-01 1996-11-19 Xoma Corporation Vectors with pectate lyase signal sequence
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
ES2150428T3 (es) 1987-04-27 2000-12-01 Unilever Nv Ensayos de union especifica.
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
DE69232002T2 (de) 1991-06-07 2002-06-06 Johnson & Johnson Clinical Diagnostics, Inc. Immunoassays unter Verwendung von markierten Hapten-Analogen
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
AU668159B2 (en) 1992-05-29 1996-04-26 Lilly Industries Limited Pharmaceutical compounds
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
DE69535855D1 (de) 1994-06-10 2008-11-20 Oklahoma Med Res Found Calciumbindende rekombinante antikörper gegen protein c
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
WO1998059233A1 (fr) 1997-06-23 1998-12-30 Luminex Corporation Lasers entrelaces pour une mesure de fluorescences multiples
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
RU2181297C2 (ru) 2000-06-20 2002-04-20 Эпштейн Олег Ильич Способ лечения патологического синдрома и лекарственное средство
US7163681B2 (en) 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
ATE492565T1 (de) 2002-01-31 2011-01-15 Randox Lab Ltd Immunogene, antikörper und konjugate für ketamin und dessen metaboliten
DE60334364D1 (de) 2002-02-21 2010-11-11 Univ California Behandlungsverfahren unter verwendung von anti-cd22-antikörpern
IL163666A0 (en) 2002-02-22 2005-12-18 New River Pharmaceuticals Inc Active agent delivery systems and methods for protecting and administering active agents
WO2003082877A1 (fr) 2002-03-28 2003-10-09 Eli Lilly And Company Aryles benzodiazepines a substitution de piperazine et leur utilisation en tant qu'antagonistes de recepteur de dopamine dans le traitement de troubles psychotiques
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
US20040127489A1 (en) 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
DK1546134T3 (da) 2002-08-05 2007-09-10 Lilly Co Eli Piperazinsubstituerede arylbenzodiazepiner
US7271252B2 (en) 2003-04-22 2007-09-18 Roche Diagnostics Operations, Inc. Reagents for detecting efavirenz
KR101351122B1 (ko) 2003-05-09 2014-01-14 듀크 유니버시티 Ｃｄ２０-특이적 항체 및 이를 이용한 방법
PL1658277T3 (pl) 2003-08-18 2012-10-31 H Lundbeck As Sól bursztynianowa i malonianowa trans-4-((1R,3S)-6-chloro-3-fenyloindan-1-ylo)-1,2,2-tri-metylopiperazyny i zastosowanie jako lek
WO2005028458A1 (fr) 2003-09-23 2005-03-31 Fermion Oy Procede de preparation de quetiapine
AU2004278414B2 (en) 2003-10-01 2012-05-24 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
BRPI0415531B8 (pt) 2003-10-23 2021-05-25 Otsuka Pharma Co Ltd formulação de aripiprazol injetável estéril de liberação controlada e método para a sua preparação
EP1706743B1 (fr) 2003-12-12 2009-11-18 Inverness Medical Switzerland GmbH Essai
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
WO2005103250A1 (fr) 2004-04-26 2005-11-03 Takami Matsuyama MÉDICAMENT THÉRAPEUTIQUE CONTENANT UN ANTICORPS MONOCLONAL ANTI RÉCEPTEUR BÉTA DE FOLATE (FR-β)
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
JP5249748B2 (ja) 2005-04-25 2013-07-31 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 無菌３−［２−［４−（６−フルオロ−１，２−ベンズイソオキサゾール−３−イル）−１−ピペリジニル］エチル］−６，７，８，９−テトラヒドロ−９−ヒドロキシ−２−メチル−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンパルミチン酸エステルの製造
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE0501418L (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP2078731A4 (fr) 2006-10-20 2012-08-01 Forerunner Pharma Res Co Ltd Composition pharmaceutique comprenant un anticorps anti-hb-egf comme ingrédient actif
EP2077860B1 (fr) 2006-10-25 2014-04-09 Ramot at Tel-Aviv University Ltd Agents psychotropes présentant une activité sur les récepteurs nmda du glutamate
US20080138842A1 (en) 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
CA2672581A1 (fr) 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anticorps monoclonal anti-claudine 3, et traitement et diagnostic du cancer au moyen d'un tel anticorps
ES2405364T3 (es) 2006-12-29 2013-05-30 Abbott Laboratories Ensayo diagnóstico para la detección de una molécula o fármaco en sangre entera
CN101600716A (zh) 2007-01-08 2009-12-09 阿特维斯集团公司 用于制备9-羟基-3-(2-氯乙基)-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮盐酸盐的改进方法
CN101245065B (zh) 2007-02-14 2010-05-19 江苏恩华药业股份有限公司 制备苯并异噁唑衍生物的方法及其中间体
CA2699062A1 (fr) 2007-09-27 2009-04-02 Novartis Ag Test de pharmacovigilance
EP3338795A1 (fr) 2008-07-21 2018-06-27 Probiodrug AG Dosage d'anticorps de diagnostic
AU2009279372A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
AU2009305203B2 (en) 2008-10-14 2013-03-07 Entasis Therapeutics Limited Fused, spirocyclic heteroaromatic compounds for the treatment of bacterial infections
WO2010096117A2 (fr) 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Procédés de traitement d’une psychose et de la schizophrénie basés sur des polymorphismes du gène erbb4
EP2194048A1 (fr) 2008-12-02 2010-06-09 Dirk Sartor Esters de nitrate pour le traitement de maladies vasculaires et métaboliques
AU2010206376B2 (en) 2009-01-26 2012-10-18 Egalet Ltd. Controlled release formulations with continuous efficacy
EP2406288B1 (fr) 2009-03-10 2016-12-14 Baylor Research Institute Vaccins ciblés vers des cellules présentant des antigènes
CA2937222C (fr) 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Promedicaments de composes nh acides
RU2554854C9 (ru) 2009-07-31 2017-02-03 Асцендис Фарма Ас Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
US20120282173A1 (en) 2009-08-17 2012-11-08 Forerunner Pharma Research Co., Ltd. Pharmaceutical composition comprising anti-hb-egf antibody as active ingredient
US20130053405A1 (en) 2009-10-06 2013-02-28 Ulrich Hersel Carrier linked paliperidone prodrugs
EP2343296A1 (fr) 2009-12-01 2011-07-13 Chemo Ibérica, S.A. Procédé pour la purification de la palipéridone
CA2927380C (fr) 2009-12-31 2017-07-04 Kempharm, Inc. Conjugues d'acides amines de quetiapine, procede de fabrication et d'utilisation de ceux-ci
WO2011112657A1 (fr) 2010-03-11 2011-09-15 Kempharm, Inc. Conjugués d'acides gras et de quétiapine, leur procédé de fabrication et leur utilisation
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (fr) 2010-06-15 2011-12-22 The Regents Of The University Of California Procédé et dispositif pour la détection d'analytes
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
WO2011163594A2 (fr) 2010-06-24 2011-12-29 Alkermes, Inc. Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates
WO2012003418A2 (fr) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Ligands fonctionnellement sélectifs des récepteurs d2 de dopamine
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP2741778A1 (fr) 2011-08-12 2014-06-18 Ascendis Pharma A/S Promédicaments liés à des excipients polymériques hyperbranchés
AU2012296949B2 (en) 2011-08-12 2016-09-15 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
WO2013088255A1 (fr) 2011-12-15 2013-06-20 Alkermes Pharma Ireland Limited Promédicaments de composés amine secondaires
BR112015003393A2 (pt) 2012-08-16 2017-07-04 Janssen Pharmaceutica Nv pirazóis substituídos como bloqueadores de canal de cálcio de tipo-n
PL3663317T3 (pl) 2012-08-21 2023-06-05 Janssen Pharmaceutica Nv Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PT3462173T (pt) * 2012-08-21 2021-04-28 Janssen Pharmaceutica Nv Anticorpos contra risperidona e utilização dos mesmos
CN110054694B (zh) * 2012-08-21 2024-02-20 詹森药业有限公司 阿立哌唑半抗原的抗体及其用途
CA2882454C (fr) 2012-08-21 2020-08-11 Matthew Garrett DONAHUE Haptenes de l'olanzipine
PL3321254T3 (pl) 2012-08-21 2021-01-11 Janssen Pharmaceutica Nv Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
WO2014031645A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc Anticorps dirigés contre des haptènes de rispéridone et leur utilisation
JP6216926B2 (ja) 2012-08-21 2017-10-25 ヤンセン ファーマシューティカ エヌ．ベー． オランザピンに対する抗体及びその使用
AU2013305879B2 (en) 2012-08-21 2017-10-12 Saladax Biomedical Inc. Antibodies to aripiprazole and use thereof
US20140057303A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Antibodies to Olanzapine Haptens and Use Thereof
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
EP2888263B1 (fr) * 2012-08-21 2018-05-09 Janssen Pharmaceutica NV Haptènes de rispéridone et de palipéridone
PL3333195T3 (pl) 2012-08-21 2021-02-22 Janssen Pharmaceutica Nv Przeciwciała względem kwetiapiny i ich zastosowania
AU2013305930B2 (en) 2012-08-21 2017-08-24 Saladax Biomedical Inc. Haptens of paliperidone
CA2882489A1 (fr) 2012-08-21 2014-02-27 Ortho-Clinical Diagnostics, Inc. Anticorps diriges contre des haptenes de paliperidone et leur utilisation
EP3305784B1 (fr) 2012-08-21 2020-08-12 Janssen Pharmaceutica NV Haptènes de quétiapine à utiliser dans des dosages immunologiques
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
AU2016372069A1 (en) 2015-12-17 2018-06-07 Saladax Biomedical Inc. Antibodies to risperidone and use thereof
WO2017106508A1 (fr) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Anticorps dirigés contre la quétiapine et utilisation associée

Also Published As

Publication number Publication date
CN108431040A (zh) 2018-08-21
AU2016372069A1 (en) 2018-06-07
JP6949025B2 (ja) 2021-10-13
US10444250B2 (en) 2019-10-15
CA3008809A1 (fr) 2017-06-22
US10852313B2 (en) 2020-12-01
JP2019504013A (ja) 2019-02-14
EP3390449A1 (fr) 2018-10-24
US20200033370A1 (en) 2020-01-30
CN108431040B (zh) 2022-07-26
US20170176473A1 (en) 2017-06-22
WO2017106501A1 (fr) 2017-06-22

Similar Documents

Publication Publication Date Title
MA47311A (fr) Anticorps anti-tgf-bêta et leur utilisation
EP3448412A4 (fr) Anticorps anti-vista humain et leur utilisation
EP3572427A4 (fr) Anticorps ciblant bcma et son utilisation
EP3575318A4 (fr) Anticorps anti-pd-1 et son utilisation
EP3626825A4 (fr) Anticorps anti-cdh6 et conjugué anticorps anti-cdh6-médicament
EP3442567A4 (fr) Anticorps anti-psma et leur utilisation
MA46525A (fr) Anticorps anti-lag-3 et compositions
EP3334757A4 (fr) Anticorps anti-tigit
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
EP3498840A4 (fr) Anticorps anti-lag-3
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA52284A (fr) Anticorps anti-hla-g et leur utilisation
EP3297671A4 (fr) Anticorps anti-ror1
MA52285A (fr) Anticorps multispécifiques et leur utilisation
EP3302442A4 (fr) Formes galéniques et leur utilisation
EP3423089A4 (fr) Anticorps anti-tigit
EP3397276A4 (fr) Anticorps et conjugués de ceux-ci
PL3653221T3 (pl) Przeciwciała anty-pvrig i sposoby ich zastosowania
EP3333192A4 (fr) Anticorps dirigé contre le glypican-3 et application associée
EP3265113A4 (fr) Anticorps anti-lilrb et leur utilisation pour détecter et traiter un cancer
EP3349787A4 (fr) Anticorps cd47 thérapeutiques
EP3307274A4 (fr) Anticorps anti-cd123 et conjugués de ceux-ci
MA47472A (fr) Anticorps
EP3492591A4 (fr) Anticorps anti-b7-h4
EP3526247A4 (fr) Anticorps anti-il1-rap